-
Heidelberg Epignostix appoints co-founder Prof. Dr. Dr. med. Felix Sahm as Chief Medical Advisor
Heidelberg, Germany, June 1, 2026 – Heidelberg Epignostix GmbH, a deeptech company committed to transforming cancer diagnostics through DNA methylation-based AI classification, today announces the appointment of Prof. Dr. Dr. med. Felix Sahm, MD, PhD, MBA as Chief Medical Advisor. In this new role, Felix will advise the company’s clinical and medical strategy as Heidelberg Epignostix…
-
Epignostix launches advanced DNA methylation-based sarcoma classifier
Heidelberg, Germany, July 8, 2025 – Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of a substantial update to their sarcoma tumour classifier- marking a substantial milestone in establishing precision tumour classification beyond tumours of the central nervous system. Combining epigenetics with artificial intelligence-powered bioinformatics, their software algorithms enable precise cancer classification of…
-
Epignostix announces CMS release of a preliminary gapfill price for their proprietary CPT Code for the Epignostix CNS Tumor Methylation Classifier test
Heidelberg, Germany, May 6, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics, announces today that the Centers for Medicare & Medicaid Services (CMS) have released a preliminary Medicare reimbursement rate for the CPT® (Current Procedural Technology) code for the Company’s proprietary Epignostix CNS Tumor Methylation Classifier – a molecular test for precision diagnostics of tumors of the central nervous…
